| Project/Area Number |
16K20595
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Surgical dentistry
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 口腔癌 / 治療抵抗性 / 高次エピゲノム / DNAメチル化 / ヒストン修飾 / エピゲノム治療 / エピゲノム / 放射線耐性 / 高悪性 / 高転移 |
|---|
| Outline of Final Research Achievements |
Oral squamous cell carcinoma (OSCC) has been increased morbidity, and its high malignant potential, including metastasis and therapeutic resistance affects patient survival. Herein, we investigated the higher-order epigemomic alteration in therapeutic resistance of OSCC to develop the novel diagnostic methods and epigenome therapy based on epigenome profile. Bromodomain containing 4 (BRD4) associates with acetylated chromatin and facilitates transcriptional activation. BET inhibitor JQ1 suppressed cell proliferation, migration and invasion in OSCC cell lines, and JQ1 reduced expression levels of matrix metalloproteinase 2 (MMP2), which are associated with cancer metastasis. These results suggest that BRD4 may be a novel therapeutic target in OSCC.
|
